Trials / Completed
CompletedNCT00741442
A Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout
Randomized, Double-Blind, Multicenter,Placebo-Controlled, Dose Ranging, Efficacy and Safety Study of RDEA806 in Hyperuricemic Subjects With Symptomatic Gout
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Ardea Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether RDEA806 is effective in the treatment of hyperuricemia in gout patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RDEA806 | Uricosuric agent for the treatment of gout |
| DRUG | Placebo | Matching Placebo. |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2009-04-01
- Completion
- 2009-09-01
- First posted
- 2008-08-26
- Last updated
- 2014-02-06
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT00741442. Inclusion in this directory is not an endorsement.